We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Spectral Medical Inc.
An SI Board Since October 2011
Posts SubjectMarks Bans Symbol
366 9 0 EDTXF
Emcee:  Sultan Type:  Unmoderated
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment for severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively in more than 80,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010, signed an exclusive distribution agreement for this product in Canada . More than 250,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI.

For further information please visit
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
366Spectral Medical Inc. Announces Proposed Public Offering of Common Shares NOT Sultan-March 6
365More insider Buys canadianinsider.comSultan-February 23
364Insider Trading canadianinsider.comSultan-February 13
363February Presentation spectraldx.comSultan-February 8
362Baxter and Spectral Medical Announce Exclusive Distribution Agreement for Blood Sultan-February 4
361J. P. Morgan Healthcare Conference [graphic]Sultan-January 10
360Spectral moving into a new range.. Last trade 0.74 .. Volume 240k .. Up 5.71% OSultan-12/11/2019
359Paradigm Capital launches coverage of Spectral Medical with a “Buy cantechletteSultan-11/5/2019
357New October Presentation spectraldx.comSultan-10/14/2019
355Spectral Medical Launches the Tigris Trial TORONTO, Sept. 24, 2019 (GLOBE NEWSWSultan-9/24/2019
354September 25-October 2, 2019 European Society of Intensive Care Medicine (ESICMSultan-9/12/2019
353New Corporate Website
352Spectral Medical Provides Corporate Update TORONTO, Aug. 08, 2019 (GLOBE NEWSWISultan-8/8/2019
351Spectral Medical Announces New Chief Financial Officer
349Trump aims to shake up kidney care market politico.comSultan-7/9/2019
348Corporate Presentation renmarkfinancial.comSultan-7/4/2019
347Cappuccino with Claudio Ronco: youtu.beSultan-6/24/2019
346Why Dialysis Is Heading Home carecentrix.comSultan-5/24/2019
345AGM . June 4th Corporate presentations on June 5th & 6th at Renmark FinanciSultan-5/22/2019
344The wind changed direction and the big river still flows: from EUPHRATES to TIGRSultan-5/21/2019
343Cost savings, disruption threat pushing more providers into home dialysis moderSultan-5/12/2019
342Spectral Announces First Quarter Results
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):